Report

Diaceutics | 1H24 trading update - continued strong performance

Diaceutics has continued its strong performance and growth across the business in 1H24. The company expects to report revenue for the half of c£12.3m, up 24% YoY or up 28% on a constant currency basis. The quality of earnings continues to improve with approximately 55% of all revenue in the period being recurring (1HFY23 47%, FY23 52%). Cash and net cash at 30 June were £16.7m, flat with YEFY23, despite continued investment into the business, in line with the accelerated growth strategy. The results are in line with the Board's expectations and look consistent with our current forecasts. Peter Keeling will become Non-Executive Chair on 1 October 2024, following the resignation of Deborah Davis.
Underlying
Diaceutics

Provider
Capital Access Group
Capital Access Group

Capital Access Group advises companies on effective engagement with investors. Our experienced team offers market-leading access with hard-to-reach investors, including smaller institutions, pension funds and private client fund managers. These under-serviced investors are located not only in London but across the regions of the UK and Europe. We have an unrivalled knowledge of this extensive audience, to whom our published research is distributed, as well as to larger institutions. We offer this service as part of an integrated investor communications strategy to promote a company’s investment story.

Our clients, ranging from AIM to FTSE 100 companies, benefit from our professional, long-term relationships with investors. Not only do we identify and target investors, we contact them directly and relay their views back to clients with analysis, interpretation and advice. This ensures that our clients are in control of their investor engagement. The objective is to improve the reach and engagement with investors, which in turn strengthens the share price.

Analysts
Colin Smith

Other Reports on these Companies
Other Reports from Capital Access Group

ResearchPool Subscriptions

Get the most out of your insights

Get in touch